Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Psychosom Med. 2011 Dec 30;74(1):46–54. doi: 10.1097/PSY.0b013e31824152ed

Table 2.

Baseline Mean ± SEM for All mRNAs Relative to TF2B

Controls (n=23; 19 F) CFS Patients (n=22; 19F) MS Patients (n=20; 18F) P1 η2
Metabolite Detecting
ASIC3 9.54E-03 ± 8.94E-04 8.26E-03 ± 1.19E-03 9.46E-03 ± 8.27E-04 0.59 .01
P2X4 1.99E-01 ± 1.84E-02 1.97E-01 ± 2.08E-02 1.70E-01 ± 1.08E-02 0.45 .03
P2X5 2.85E-01 ± 3.48E-02 2.68E-01 ± 3.07E-02 3.06E-01 ± 3.75E-02 0.74 .02
TRPV1 1.42E-02 ± 1.52E-03 1.28E-02 ± 1.41E-03 1.36E-02 ± 7.28E-04 0.74 .01
Adrenergic
α-2a 3.51E-03 ± 3.82E-04 3.11E-03 ± 5.28E-04 6.47E-03 ± 1.68E-03* 0.04 .12
β-1 9.22E-03 ± 2.47E-03 2.31E-02 ± 1.17E-02 8.96E-03 ± 2.70E-03 0.30 .04
β-2 1.15E+00 ± 1.79E-01 8.85E-01 ± 7.92E-02 8.99E-01 ± 6.43E-02 0.22 .04
COMT 1.89E-01 ± 1.36E-02 1.86E-01 ± 2.34E-02 2.19E-01 ± 2.05E-02 0.44 .04
Immune
IL-6 5.58E-03 ± 2.55E-03 4.28E-03 ± 6.33E-04 4.98E-03 ± 9.28E-04 0.85 .01
IL-10 4.90E-03 ± 6.14E-04 3.56E-02 ± 2.84E-02 5.77E-03 ± 6.60E-04 0.34 .03
Lymphotoxin-α 9.51E-02 ± 1.47E-02 9.62E-02 ± 2.31E-02 1.54E-01 ± 3.59E-02 0.20 .05
TLR4 4.84E-01 ± 1.27E-01 4.94E-01 ± 6.62E-02 3.98E-01 ± 5.59E-02 0.72 .01
CD14 1.74E+00 ± 1.46E-01 2.23E+00 ± 2.91E-01 2.09E+00 ± 2.32E-01 0.30 .04

Table values are mRNA counts relative to control gene TF2B (mean ± SE)

1

p values calculated using oneway ANOVA

*

p<.05 vs controls, using post hoc Dunnett test

HHS Vulnerability Disclosure